Search
Digoxin
go.drugbank.com/drugs/DB00390ApprovedInvestigational[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. … [L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.
Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalHowever, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled … It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner.
Synonyms: (5α,17β)-N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamideEplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigationalEplontersen is a transthyretin-directed antisense oligonucleotide with 3 covalently linked e N-acetyl galactosamine residues for hepatic delivery. … [A262975] Hereditary transthyretin-mediated amyloidosis is caused primarily by pathogenic variants of the TTR gene, leading to the formation and thus accumulation of insoluble and misfolded amyloid in
Dextran
go.drugbank.com/drugs/DB09255ApprovedInvestigationalVet approvedIt is administered by intravenous infusion. Dextran 75 is a complex branched glucan with an average molecular weight 75000 Daltons. … The main chain of glucose has short branches at frequent intervals which are probably joined by 1:3 and 1:4 glucoside links. The chains can be composed of about 200,000 glucose units.
Mixtures: Leader Dry Eye Relief, Leader Dry Eye ReliefAbrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAtopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and the aberrant activation of immune cells. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Tegaserod
go.drugbank.com/drugs/DB01079ApprovedWithdrawn[L5918,F4229] Zelnorm (tegaserod) by Sloan Pharma subsequently gained re-approval in April of 2019.[L5918] Nevertheless, tegaserod remains un-approved in certain regions. … Novartis' brand name Zelnorm (tegaserod) had originally received approval from the US FDA in 2002 for the treatment of irritable bowel syndrome with constipation (IBS-C).
Resorcinol
go.drugbank.com/drugs/DB11085ApprovedInvestigationalResorcinol works by helping to remove hard, scaly, or roughened skin. … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic
Cilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalThe first combination product containing both drugs was approved by the FDA in November of 1985 under the trade name Primaxin, marketed by Merck & Co. … Since the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism.
Synonyms: (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine, (Z)-7-((R)-2-Amino-2-carboxy-ethylsulfanyl)-2-[((S)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acidChenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalIt works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.
Plicamycin
go.drugbank.com/drugs/DB06810ApprovedWithdrawnPlicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus.